ROIV (Roivant Sciences) Total Long-Term Assets: $541.30 Mil (As of Mar. 2026)


ROIV Roivant Sciences Ltd ROIV
51 GF Score
Price $35.14
GF Value $11.11
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roivant Sciences Total Long-Term Assets?

Roivant Sciences ROIV +0.29% 51 Total Long-Term Assets is $541.30 Mil as of Mar. 2026. GuruFocus rates ROIV with a GF Score™ of 51/100 and a GF Value™ of $11.11 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Roivant Sciences's Total Long-Term Assets for the quarter that ended in Mar. 2026 was $541.30 Mil.

Roivant Sciences Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Roivant Sciences's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roivant Sciences Total Long-Term Assets Chart

Roivant Sciences Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Long-Term Assets
Get a 7-Day Free Trial 438.61 591.02 490.65 436.88 541.30

Roivant Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 436.88 416.85 550.95 565.48 541.30
ROIV
51GF Score
Roivant Sciences Ltd ROIV
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roivant Sciences Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $541.30 Mil mean?
Roivant Sciences (ROIV) has a Total Long-Term Assets of $541.30 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Roivant Sciences and its competitors.
Is Roivant Sciences' Total Long-Term Assets too high?
Roivant Sciences' current Total Long-Term Assets is $541.30 Mil. Overall, Roivant Sciences has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' Total Long-Term Assets compare to RPRX and BNTX?
Roivant Sciences' Total Long-Term Assets of $541.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Roivant Sciences and its competitors. Roivant Sciences's current Total Long-Term Assets is $541.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Based on GuruFocus' analysis, Roivant Sciences (ROIV) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.11, compared to a current price of $35.14 — trading 216.3% above its estimated fair value. The current Total Long-Term Assets is $541.30 Mil. Roivant Sciences' overall GF Score™ is 51/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Roivant Sciences (ROIV), the current Total Long-Term Assets is $541.30 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roivant Sciences (ROIV) Overvalued in 2026?

Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued. The current stock price of $35.14 is trading 216.3% above its estimated GF Value™ of $11.11. GuruFocus considers Roivant Sciences to be Significantly Overvalued.

Key valuation signals for ROIV:

  • Total Long-Term Assets: $541.30 Mil
  • GF Value™: $11.11 vs. price of $35.14 (216.3% above fair value)
  • GF Score™: 51/100 with 7 warning signs

No single metric tells the full story. See the ROIV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roivant Sciences Business Description

Other Exchanges 87S:Germany
Address 50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
51GF Score

Get the complete analysis for ROIV

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.14
Price
$11.11
GF Value